Insulin-like growth factor binding protein-2 as a novel biomarker for disease activity and renal pathology changes in lupus nephritis
Insulin-like growth factor binding protein-2 as a novel biomarker for disease activity and renal pathology changes in lupus nephritis
复制标题
胰岛素样生长因子结合蛋白2作为狼疮性肾炎疾病活动度及肾脏病理改变的新型生物标志物
DOI：
10.1111/cei.12743
复制
发表时间：
2016-04-01
影响因子：
4.6
通讯作者：
Wu, T.
中科院分区：
文献类型：
--
作者：
Ding, H.;Kharboutli, M.;Wu, T.
狼疮性肾炎(LN)是系统性红斑狼疮最严重的表现之一。侵袭性肾活检仍然是诊断和治疗狼疮性肾炎的金标准。本研究的目的是验证血清胰岛素样生长因子结合蛋白-2(IGFBP-2)作为一种新的LN临床疾病和肾脏病理的生物标志物。对85例经活检证实的狼疮性肾炎患者、18例慢性肾脏病(CKD)患者和20例健康对照进行了血清IGFBP-2的酶联免疫吸附试验(ELISA)检测。LN患者血清IGFBP-2水平显著高于非狼疮性CKD患者和健康对照组。血清IGFBP2可区分LN患者和其他两组患者[LN与CKD的曲线下面积(AUC)=0 65，95%可信区间(CI)=0 5 2~0 78；P=0 0 43；LN与健康对照的P<；00001]。血清IGFBP-2水平与血肌酐水平呈正相关(r=0658，P
Lupus nephritis (LN) is one of the most serious manifestations of systemic lupus erythematosus. Invasive renal biopsy remains the gold standard for the diagnosis and management of LN. The objective of this study is to validate serum insulin-like growth factor binding protein-2 (IGFBP-2) as a novel biomarker for clinical disease and renal pathology in LN. Eighty-five biopsy-proven lupus nephritis patients, 18 chronic kidney disease (CKD) patients and 20 healthy controls were recruited for enzyme-linked immunosorbent assay (ELISA) testing of serum IGFBP-2 levels. Compared to CKD patients of origins other than lupus or healthy controls, serum IGFBP-2 levels were elevated significantly in LN patients. Serum IGFBP-2 was able to discriminate LN patients from the other two groups of patients [area under the curve (AUC)=065, 95% confidence interval (CI)=052-078; P = 0043 for LN versus CKD; 097, 95% CI=093-100; P < 00001 for LN versus healthy controls]. Serum IGFBP-2 was a potential indicator of both global disease activity and renal disease activity in LN patients, correlated with serum creatinine levels (r=0658, P